ACADIA Pharmaceuticals (ACAD) vs Legend Biotech (LEGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ACADIA Pharmaceuticals (ACAD) has outperformed Legend Biotech (LEGN) over the past year, losing 8.8% versus a loss of 39.1%. Over five years, ACAD leads with a +12.2% price change compared with -63.2% for LEGN. Legend Biotech is the larger company by market cap ($3.59 billion vs $3.40 billion), about 1.1 times the size.
On valuation, Legend Biotech trades at a lower forward P/E (17.6x vs 22.2x for ACADIA Pharmaceuticals). ACADIA Pharmaceuticals converts more of its revenue into profit, with a net margin of 36.5% versus -28.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACAD | LEGN |
|---|---|---|
| Share price | $19.71 | $18.45 |
| Market cap | $3.40B | $3.59B |
| 1-day change | +0.31% | -3.50% |
| YTD return | -26.43% | -12.05% |
| 1-year return | -8.77% | -39.13% |
| 5-year return | +12.22% | -63.17% |
| P/E ratio (TTM) | 8.84 | — |
| Forward P/E | 22.18 | 17.57 |
| EPS (TTM) | $2.23 | $-0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.07B | $1.03B |
| Revenue growth (YoY) | +11.87% | +64.04% |
| Net income (latest FY) | $391.00M | $-296.80M |
| Gross margin | 91.69% | 61.41% |
| Operating margin | 9.78% | -13.27% |
| Net margin | 36.49% | -28.85% |
| 52-week high | $30.96 | $37.50 |
| 52-week low | $19.32 | $16.24 |
| Distance from 52-week high | -36.34% | -50.80% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +63.17% | +152.03% |
| Average volume | 1.84M | 2.36M |
| Shares outstanding | 172.31M | 194.49M |
| Employees | 796 | 3,200 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACAD has outperformed LEGN by 30.4 percentage points over the past year.
- ACADIA Pharmaceuticals is more profitable, keeping 36.5 cents of every revenue dollar as net income versus -28.8 cents for Legend Biotech.
- Legend Biotech grew revenue faster in its latest fiscal year (+64.04% vs +11.87%).
About ACADIA Pharmaceuticals
ACAD stock →ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Health Care · Biotechnology: Pharmaceutical Preparations · 796 employees
About Legend Biotech
LEGN stock →Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).
Health Care · Biotechnology: Pharmaceutical Preparations · 3,200 employees
ACAD vs LEGN FAQ
Which is bigger, ACADIA Pharmaceuticals or Legend Biotech?
Legend Biotech (LEGN) is larger, with a market capitalization of $3.59B compared with $3.40B for ACADIA Pharmaceuticals (ACAD).
Which stock has performed better over the past year, ACAD or LEGN?
ACAD returned -8.77% over the past 12 months, compared with -39.13% for LEGN (price return, excluding dividends). Past performance does not predict future results.
Are ACADIA Pharmaceuticals and Legend Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.